Source: MONTANA STATE UNIVERSITY submitted to NRP
PATHOGENESIS OF HORSE PATHOGEN STREPTOCOCCUS EQUI
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
COMPLETE
Funding Source
Reporting Frequency
Annual
Accession No.
1002530
Grant No.
(N/A)
Cumulative Award Amt.
(N/A)
Proposal No.
(N/A)
Multistate No.
(N/A)
Project Start Date
Oct 1, 2014
Project End Date
Sep 30, 2019
Grant Year
(N/A)
Program Code
[(N/A)]- (N/A)
Recipient Organization
MONTANA STATE UNIVERSITY
(N/A)
BOZEMAN,MT 59717
Performing Department
Microbiology & Immunology
Non Technical Summary
The ultimate goal of this project is to identify new virulence factors and protective antigens for the development of an effective strangles vaccine against S. equi infection. This pathogen is the causative agent of strangles, a highly contagious purulent lymphadenitis and one of the most common infectious diseases in horses. The currently available vaccine has safety and efficiency issues. Difficulty to develop a safe and efficacious strangles vaccine by others and us is the lack of full understanding of S. equi pathogenesis. In particular, how S. equi virulence genes are regulated is not known. This project proposes a virulence regulation-based approach to identify new virulence factors and protective antigens. This approach is based on the high homology of S. equi and human pathogen group A Streptococcus (GAS) in genetic content and the knowledge of regulation of GAS virulence genes by the two-component regulatory system CovRS and the transcription regulator Mga. We hypothesize that the homologues of GAS CovRS and Mga in S. equi, SeCovRS and SeMga, regulate its virulence genes and that the SeCovRS and SeMga regulons contain uncharacterized virulence genes. We will pursue two objectives: 1) Determine whether SeCovRS and SeMga regulate S. equi virulence and identify what genes are regulated by SeCovRS and SeMga and 2) identify new virulence factors and protective antigens among SeCovRS- and SeMga- regulated genes. The project will advance the understanding of S. equi pathogenesis and have the potential to identify new protective antigens for developing a safe and effective strangles vaccine.
Animal Health Component
(N/A)
Research Effort Categories
Basic
100%
Applied
(N/A)
Developmental
(N/A)
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
31138101100100%
Knowledge Area
311 - Animal Diseases;

Subject Of Investigation
3810 - Horses, ponies, and mules;

Field Of Science
1100 - Bacteriology;
Goals / Objectives
The ultimate goal of this project is to identify new virulence factors and protective antigens for the development of an effective strangles vaccine against Streptococcus equi infection. Based on the homology of S. equi with the human pathogen Group A Streptococcus and the facts that the transcription regulators CovRS and Mga regulate GAS virulence genes, we hypothesize that the homologues of GAS CovRS and Mga in S. equi, SeCovRS and SeMga, regulate its virulence genes and that the SeCovRS and SeMga regulons contain uncharacterized virulence genes. We will achieve our goal by defining the SeCovRS and SeMga regulons and identifying new virulence factors and protective antigens among SeCovRS- and SeMga- regulated genes.Objective 1: Determine whether SeCovRS and SeMga regulate S. equi virulence and define SeCovRS and SeMga regulonsThe secovR and semga genes of S. equi will be deleted. Resulting S. equi mutants will be compared with their parent strain in virulence and transcription profile using cDNA microarray analysis. Genes with substantial alteration in transcription will be confirmed by real-time reverse transcriptase PCR. The milestone for this objective is that genes regulated by SeCovRS and SeMga are identified.Objective 2: Identify novel virulence factors and protective antigens among the genes in the SeCovRS and SeMga regulonsTarget genes will be inactivated. Resulting mutants will be compared with their parent strain in virulence using mouse model of intranasal S. equi infection. Identified virulence factors will be further tested for their potential as protective antigens using immunization and challenge with the mouse model. The milestone for this objective is to find that several SeCovRS- and SeMga-regulated genes contribute to S. equi virulence and corresponding proteins provide protection against S. equi infection in mouse immunization and challenge experiment.
Project Methods
1. Determine whether SeCovRS and SeMga regulate S. equi virulence genes and define the SeCovRS and SeMga regulonsWe will first generate deletion mutants of S. equi for the secovR and semga genes. Next, we will determine whether SeCovRS and SeMga regulate S. equi virulence by comparing mutants with wild-type strain in intranasal infection of mice in which we will compare survival rates, throat colonization, and S. equi load in blood, lung and spleen. Next, we will evaluate the resistance of these mutants to phagocytosis and killing by horse neutrophils. Finally, we will define the SeCovRS and SeMga regulons.Generation of secovR and semga deletion mutants. We will use gene replacement to generate secovR and semga deletion mutants of S. equi. The two flanking fragments of target gene will be cloned into pGRV to obtain a suicide plasmid, which will be introduced into S. equi by electroporation. Double crossover between the flanking fragments and S. equi genome DNA will result in deletion mutant of targeted gene, which will be selected by antibiotic spectinomycin and confirmed by PCR and DNA sequencing analyses.Intranasal infection of mice. To determine whether SeCovRS and SeMga regulate S. equi virulence, we will compare the secovR and semga deletion mutants with wild-type S. equi strains in virulence, throat colonization, and dissemination. In the test, each strain at 108 colony-forming units (cfu) in 10 µl will be inoculated in one nostril. The mice will be monitored daily to determine survival rates using a scaled endpoint and will be swabbed on day 2 after inoculation to measure throat colonization. Some of the mice will be sacrificed to collect blood and organs to measure S. equi load.Evaluation of the resistance of secovR and semga deletion mutants to phagocytosis and killing by neutrophils. S. equi(delta)secovR and S. equi(delta)semga mutants will be compared with parent strain in growth and survival in horse blood and in phagocytosis by equine neutrophils. If our hypotheses are correct, we expect that S. equi(delta)semga loses resistance to phagocytosis and killing by neutrophils and cannot survive in blood. In contrast, S. equi(delta)secovR will show higher resistance to phagocytosis and killing by neutrophils and survive better in blood.Microarray analysis and real-time RT-PCR. Total RNA will be isolated from wild-type S. equi and its secovR and semga deletion mutants at exponential phase with Qiagen RNeasy kits, as described previously (38). Labelled cDNA will be generated from S. equi RNA and hybridized to NimbleExpress S. equi arrays, which will be designed and produced by Nimblegen using the S. equi genome database. The FlexArray program will be used to identify genes with ? 10 fold in secovR mutant and ?10 fold in semga mutant compared with parent strain. Alteration in expression of genes identified will be confirmed by real-time RT-PCR.2. Identify novel virulence factors and protective antigens among the genes in the SeCovRS and SeMga regulonsWe will examine the contribution of selected uncharacterized SeCovRS- and SeMga-regulated genes to S. equi virulence. We will next evaluate the potential of selected virulence factors identified as candidate vaccine antigens.Identification of new virulence factors. This objective will be achieved by first generating gene deletion mutants and then comparing mutants with parent strain using the mouse model of intranasal S. equi infection. The deletion of target genes and mouse infection will be conducted as described above. The Mga regulon is critical for the survival of GAS in non-immune blood. We are particularly interested in whether semga deletion mutant of S. equi cannot survive in mouse blood or not. If not, we will generate double and triple mutants if necessary to identify a set of genes that are required for S. equi survival against neutrophil responses. We will test mutants in blood growth and phagocytosis assays In blood growth assay, ∼104?colony-forming units (cfu) of S. equi and its mutants will be inoculated in 0.5 ml heparinized non-immune blood. The samples are rotated end-to-end at 37?°C for 4 h, and numbers of viable S. equi in the samples and actual inocula are determined by plating on THY agar. Growth factor is defined as the ratio of cfu of each sample after 4-h incubation to cfu in the inoculum. In phagocytosis assay, S. equi bacteria will be labeled with 0·75 μg/ml−1 FITC in phosphage-buffered saline (PBS) at 37?°C for 20?min. The labeled bacteria are washed and resuspended at 1×109 cfu/ml in PBS.Ten μl of the labeled bacteria is mixed with 100 μl heparinized mouse blood and incubated with gentle shaking at 37°C for 0, 15, and 30 min. The samples are immediately processed using an Immunolyse kit (Beckman Coulter) according to the manufacturer's protocol and analyzed by flow cytometry. The percentage of neutrophils with fluorescent bacteria is used as a measurement of phagocytosis efficiency.Evaluation of novel virulence factors for the potential as protective vaccine antigens. Selected virulence genes identified will be PCR cloned into pET21b at the restriction sites of NdeI and EcoRI, and recombinant plasmid DNA will be introduced into E. coli BL21 strain. Overexpression of cloned genes will be achieved by IPTG induction. Overexpressed proteins will be purified using a combination of chromatography, including anion exchange, cation exchange, and hydrophobic interaction chromatography. Our laboratory has extensive experience in protein purification. Thus, we do not expect difficulty in protein preparation.Purified proteins will be evaluated for the potential as vaccine antigen candidates. CD-1 mice will be immunized by inoculating into one nostril with 10 ml phosphate-buffered saline (PBS) of 10 mg protein/4 mg mouse IL-1a (adjuvant) or IL-1a (adjuvant control) on day 1. The mice will be boosted by the same treatment on day 14. On day 50, some of immunized mice in each group will be sacrificed to collect nasal wash and sera to determine titers of mucosal IgA and serum IgG antibodies; other mice will be inoculated I.N. with 1 x 108 cfu of S. equi for determining survival rates and throat colonization.In vitro evaluation of potential vaccine candidates with equine leukocytes. Promising virulence factors and protective antigens identified using mouse model will be further tested individually or in combinations for their potential as vaccine candidates using in vitro test with leukocytes. Gene deletion mutants and specific antibodies of identified potential virulence factors and vaccine candidates will be tested in whole blood growth/survival assays involving equine leukocytes. We hope to identify S. equi mutants defective in virulence genes cannot resist to neutrophil phagocytosis and killing and thus can be effectively killed by equine neutrophils, and relevant specific antibodies can enhance opsonophagocytosis and killing of S. equi by equine neutrophils.

Progress 10/01/14 to 09/30/19

Outputs
Target Audience: Nothing Reported Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided?7 undergraduate students, two professionals, and two technicians conducted research for this project. The project thus provide the students with the opportunity to gain research experience in gene cloning and deletion and gene expression and regulation. Two students were coauthors for published research papers. How have the results been disseminated to communities of interest?The results were presented at three international symposium and some of the results were published. What do you plan to do during the next reporting period to accomplish the goals? Nothing Reported

Impacts
What was accomplished under these goals? The secovRS and semagA genes of Streptococcus equi were deleted, generating secovRS and semagA gene deletion mutants. The deletion mutants were compared with the parent strain in mouse model of intranasal S. equi infection, finding that these mutants were not attenuated in virulence. Then we compared the expression of the capsule synthase gene in the secovRS deletion mutant and wild-type strain and found that the secovRS deletion did not alter the expression of the capsule synthase gene. It is possible that the strain studied might have a mutation that compromised the function of SeCovRS to repress the capsule gene. To test this possibility, we sequenced the secovRS gene in 5 clinical isolates and did not find variation of the secovRS gene, ruling out the possibility. Similary, we compared the expression of the seM gene in wild-type strain and semagA deletion mutant and found no significant difference in seM gene expression.Our data suggest that, unlike in Group A Streptococcus, SeCovRS and SeMagA do not regulate major virulence factors in S. equi. We tested a mouse model of pulmonary infection using the signle and double deletion mutants of the streptolysin S and platelet-activating factor (PAF) acetylhydrolase see genes. We found that the single deletion mutants were not attenuated in virulence but the double deletion mutant was attenuated. Furthermore, we found that S. equi has the ability to invade the vascular system in this new mouse infection model.

Publications

  • Type: Journal Articles Status: Published Year Published: 2019 Citation: 1. Lei B, Minor D, Feng W, Jerome M, Quinn MT, Jutila MA, Liu M. 2019. Tissue Tropism in Streptococcal Infection: Wild-Type M1T1 Group A Streptococcus is Efficiently Cleared by Neutrophils Using an NADPH Oxidase-Dependent Mechanism in the Lung but not in the Skin. Infect Immun. 87: e00527-19.


Progress 10/01/17 to 09/30/18

Outputs
Target Audience: Nothing Reported Changes/Problems:Since the results indicate that the deletion of secovRS and semga did not have significant effects on virulence and the new data show that S. equi can invade vascular system, we will search for virulence factors that contribute to S. equi invasion of the vascular system. What opportunities for training and professional development has the project provided?One undergraduate student and one graduate student participated in this project. They acquired experience in histological analyses of infected mouse tissues. How have the results been disseminated to communities of interest?Dr. Lei gave a keynote presentation at 2nd International Conference on Microbial Pathogenesis and Infectious Diseases, Vancouver, Canada: Molecular Mechanisms of Hypervirulent Group A Streptococcus to Evade Innate Immune Responses and to Invade the Vascular System in Mouse Model of Pulmonary Infection. What do you plan to do during the next reporting period to accomplish the goals?We will search for virulence factors that contribute to vascular invasion by S. equi.

Impacts
What was accomplished under these goals? We compared the secovR and semga mutants with their parent strain in virulence in the mouse model of pulmonary infection. There were no differences in virulence among the strains. However, we found that S. equi invades the peribronchovascular interstitium in murine pulmonary infection. This phenomenon was similar to that in pulmonary infection of mice with a hypervirulent Group A Streptococcus (GAS) isolate. This GAS strain has a G1370T mutation in the sensor kinase covS gene of CovRS. Intratracheal inoculation of MGAS315 led to the lung infection that displayed extensive Gram staining at the alveolar ducts, alveoli, and peribronchovascular and perivascular interstitium. The correction of the covS mutation did not alter the infection at the alveolar ducts and alveoli but prevented GAS invasion of the peribronchovascular and perivascular interstitium. Furthermore, the covS mutation allowed MGAS315 to disrupt and degrade the smooth muscle and endothelial layers of the blood vessels, directly contributing to systemic dissemination. It is concluded that hypervirulent emm3 GAS covS mutants can invade the perivascular interstitium and directly attack the vascular system for systemic dissemination. Clinical S. equi show a similar phenotype with the hypervirulent GAS strain in peribronchovascular invasion, suggesting that S. equi may have the capacity to translocate the epithelial cells to enter the perivascular space where S. equi is drained to lymph nodes. The data also suggest that clinical S. equi isolates already have mutation in secovRS.

Publications

  • Type: Journal Articles Status: Published Year Published: 2018 Citation: Lei B, Minor D, Feng W, Liu M. 2018. Hypervirulent Group A Streptococcus of Genotype emm3 Invades the Vascular System in Pulmonary Infection of Mice. Infect Immun 86: e00080-18.
  • Type: Journal Articles Status: Published Year Published: 2018 Citation: Liu M., Lei B. 2018. Pathogenesis of hypervirulent Group A Streptococcus. Jpn J Med. 1:6:269-275


Progress 10/01/16 to 09/30/17

Outputs
Target Audience:We gave two oral presentations at "A Haveneyer Foundation Workshop: Getting to Grips with Strangles and other Streptococcal Diseases", which was held on September 19-21, 2017 at Gallatin Gateway, Montana. The workshop was attended by 41 scientists. Changes/Problems:We had expected that SeCovRS and SeMga are the critical transcription regulators for the virulence factors of S. equi. However, the results so far indicate that their deletions had no significant effect on virulence and virulence gene expression. It is likely possible that the virulence genes of S. equi are regulated by other regulators. Thus, we will test other transcription regulators, especially other two component regulatory systems of S. equi for their role in virulence regulation. What opportunities for training and professional development has the project provided?Two undergraduate students and one technician participated in this project. They acaured experience in mouse model of bacterial infection and measurement of gene expression by real-time RT qPCR. How have the results been disseminated to communities of interest?We gavethe followingoral presentations at "A Haveneyer Foundation Workshop: Getting to Grips with Strangles and other Streptococcal Diseases", which was held on September 19-21, 2017 at Gallatin Gateway, Montana: Feng W., Liu M., Minor D., and Lei B. Mouse model for pulmonary infection with Streptococcus equi subspecies equi and Group A Streptococcus Lei B., Liu M., Xie G., and Zhu H. Evaluation of a tetravalent subunit strangle vaccine. What do you plan to do during the next reporting period to accomplish the goals?We plan to compare the secovR and semga mutants with their parent strain in virulence in the mouse model of pulmonary infection. If we still observe insignificant difference, we will test other transcription regulators for their role in the regulation of virulence factors including the capsule synthase HasA.

Impacts
What was accomplished under these goals? In the second progress report for the period of 10/01/2015 to 09/30/2016, we reported unexpected results of the SecovRS mutant in terms of the effects of the CovR mutation on virulence and expression of the capsule synthase. We suspected that the strain we used might have mutation in the secovRS genes that led to the unexpected results. So we sequenced the secovRS genes of 5 clinical isolates and all had the same sequence. Thus, the unexpected results were unlikely due to a mutation of the secovRS genes. The data suggest that, unlike inGroup A Streptococcus,SecovRS may not regulatethe major virulence factors in S. equi. We compared the virulence of SeMga mutant with its parent strain using the mouse model ofintranasal infection. We did notobserve significant difference in virulence.Wealso test amouse model of pulmonary infection using the single and doubledeletion mutants of the streptolysin S andplatelet-activating factor (PAF) acetylhydrolasesee genes. We found that thesinglestreptolysin S or see deletion mutant was notattenuatedin virulence in this new model but the double mutant was attenuated. Thus, wedeveloped a newmouse infection model for S. equi thatshould be useful foridentification and evaluation virulence factors. This work was presented ina Haveneyer Foundation Workshop on Getting to Grips with Strangles and other streptococcal diseases.

Publications

  • Type: Journal Articles Status: Published Year Published: 2017 Citation: Feng W, Minor D, Liu M, Lei B. 2017. Requirement and Synergistic Contribution of Platelet-Activating Factor Acetylhydrolase Sse and Streptolysin S to Inhibition of Neutrophil Recruitment and Systemic Infection by Hypervirulent emm3 Group A Streptococcus in Subcutaneous Infection of Mice. Infect Immun. 85: e00530-17.


Progress 10/01/15 to 09/30/16

Outputs
Target Audience:The target audience includes: scientists in bacterial pathogenesis, strangle research and gene regulation and students in animal health. Changes/Problems:As described in the result, we need to figure out whether the S. equi strain had a natural SeCovRS mutation. However, this is not a major change in the approach. What opportunities for training and professional development has the project provided?Two undergraduate students, one professional, and one technician participated in this project. The project thus provide the students with the opportunity to gain research experience in gene cloning and deletion and gene expression and regulation. One student was a co-author of a recently accepted manuscript that will be published soon in Infection and Immunity. How have the results been disseminated to communities of interest? Nothing Reported What do you plan to do during the next reporting period to accomplish the goals?We will check the hasA expression in clinical S. equ isolates in our collection and sequence the SeCovRS genes to determine whether there was a natural SeCovRS mutation in the strain from which the SeCovR deletion mutant was obtained. Addressing this question is critical for the SeCovR part of the objectives. If the strain had a natural SeCovRS mutation, we will generate SeCovR mutant of a strain with wild-type SeCovRS genes if the strain and then perform transcriptome analysis. Otherwise, wewillperform transcriptome analysis for theSeCovR mutantwe have now and its parent strain. We will also compare the virulence of the SeMga deletion mutant with its parent strain in mouse model of intranasal infection.

Impacts
What was accomplished under these goals? In the first year, we got putative inactivation mutants of the SeCovR gene of Streptococcus equi. In this yearwe have confirmed the SeCovR gene inactivation by DNA sequencing. We also obtained the SeMga inactivation mutant of Streptococcus equi. We compared the virulence of the SeCovR gene deletion mutant with its parent strain using mouse model of intranasal infection. We found that the deletion of the SeCovR gene did not enahnce virulence. The result was unexpected. To figure out the reason for the unexpected result, we compared the expression levels of the hasA gene in the SeCovR deletion mutant and the parent strain, the gene encoding synthase for production of the hyaluronic capsule. Both strains expressed the high levels of the hasA transcript. CovRS suppresses hasA expression, and CovR deletion enhances hasA expression. Our results suggest that the clinical isolate may have a natural CovRS mutation that enhanced hasA expression, a frequent phenomenon in Group A Streptococcus. We will need to determine whether the S. equi strain had a CovRS mutation prior to transcriptome analysis.

Publications

  • Type: Journal Articles Status: Published Year Published: 2016 Citation: 2. Feng W, Liu M, Chen DG, Yiu R, Fang FC, Lei B. 2016. Contemporary Pharyngeal and Invasive emm1 and Invasive emm12 Group A Streptococcus Isolates Exhibit Similar In Vivo Selection for CovRS Mutants in Mice. PLoS One 11:e0162742.
  • Type: Journal Articles Status: Awaiting Publication Year Published: 2017 Citation: 1. Feng W, Minor D, Liu M, Li J, Ishaq SL, Yeoman C, Lei B. 2016. Null Mutations of Group A Streptococcus Orphan Kinase RocA: Selection in Mouse Infection and Comparison with CovS Mutations in Alteration of in vitro and in vivo Protease SpeB Expression and Virulence. Infect Immun doi:10.1128/IAI.00790-16


Progress 10/01/14 to 09/30/15

Outputs
Target Audience: Nothing Reported Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided?One undergraduate student, one technican, and a professional participated in this project. Their participation provided opportunity for them to gain experience and knowledge in microbiology and bacteriology. How have the results been disseminated to communities of interest?Some resultswill bepresented in a seminar on October 29th, 2015 for faculty, students, and researchers in the Department of Animal Sciences at Montana State University. What do you plan to do during the next reporting period to accomplish the goals?We will first confirm the inactivation of the SeCovR gene in putative mutants obtained and generate the SeMga deletion mutants. After the mutants are obtained, we will start to identify genes that are regulated by the SeCovRS and SeMga virulence regulators by comparing mutants with parent S. equi strain in transcriptome.

Impacts
What was accomplished under these goals? In the first year of this project, we mainly focused on generation of Streptococcus equi mutants that are defective in the SeCovR and SeMga genes. We have contructed plasmids for the inactivation of the SeCovR and SeMga genes, and we have obtained putative inactivation mutants of the SeCOvR gene.

Publications

  • Type: Journal Articles Status: Published Year Published: 2015 Citation: Liu G, Feng W, Li D, Liu M, Nelson DC, Lei B. 2015. The Mga Regulon but not Deoxyribonuclease Sda1 of Invasive M1T1 Group A Streptococcus Contributes to in vivo Selection of CovRS Mutations and Resistance to Innate Immune Killing Mechanisms. Infect Immun. 83:4293-4303